Clarithromycin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Clarithromycin: From Bacterial Infections to Monoclonal Gammopathy
One-Sentence Summary
Clarithromycin is a macrolide antibiotic widely used for respiratory tract infections, Helicobacter pylori eradication, and Mycobacterium avium complex (MAC) infections. The TxGNN model predicts it may be effective for Monoclonal Gammopathy (including MGUS and multiple myeloma), with 1 completed Phase 2 clinical trial and 20 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bacterial infections (respiratory tract, H. pylori eradication, MAC) |
| Predicted New Indication | Monoclonal Gammopathy |
| TxGNN Prediction Score | 98.81% |
| Evidence Level | L2 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on known pharmacology, Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis via binding to the 50S ribosomal subunit. Beyond its antibacterial properties, it is a potent CYP3A4 inhibitor and exerts significant immunomodulatory effects — including inhibition of NF-κB signalling and downregulation of pro-inflammatory cytokines such as TNF-α and IL-6.
Monoclonal gammopathy encompasses a spectrum of clonal plasma cell disorders, from the indolent pre-malignant state of MGUS (monoclonal gammopathy of undetermined significance) to symptomatic multiple myeloma. The mechanistic rationale for Clarithromycin in this disease spectrum operates on multiple levels: (1) CYP3A4 inhibition increases systemic drug exposure of immunomodulatory agents (IMiDs: thalidomide, lenalidomide, pomalidomide) and dexamethasone, effectively potentiating standard backbone regimens; (2) direct NF-κB inhibition and cytokine downregulation exert anti-myeloma effects independent of combination partners; and (3) preclinical evidence demonstrates synergistic cytotoxicity against myeloma cells when Clarithromycin is combined with IMiDs (PMID 26505646).
The clinical translation of these mechanisms is supported by multiple established combination regimens: BiRD (clarithromycin + lenalidomide + dexamethasone), BLT-D (clarithromycin + thalidomide + dexamethasone), and ClaPd (clarithromycin + pomalidomide + dexamethasone). A completed Phase 2 trial specifically targeting MGUS (NCT00006219) further validates the TxGNN prediction, and a Phase 3 RCT (Puig et al., 2021) was also conducted — lending this indication an unusually high level of clinical investigation for a repurposing candidate.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00006219 | Phase 2 | Completed | N/A | Randomized Phase 2 comparing DHEA vs clarithromycin as chemoprevention in MGUS patients at high risk of progressing to multiple myeloma; completed December 2006 |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34021118 | 2021 | Randomized Clinical Trial | Blood Cancer Journal | Phase 3 RCT (286 patients): continuous Rd ± clarithromycin in transplant-ineligible MM; no significant PFS difference at median 19 months follow-up — raises questions about the added benefit of clarithromycin over standard Rd |
| 36394758 | 2022 | Systematic Review / Meta-analysis | European Review for Medical and Pharmacological Sciences | Meta-analysis of pomalidomide + dexamethasone triplets in relapsed/refractory MM; contextualises clarithromycin-containing regimen (ClaPd) efficacy relative to other triplet options |
| 17989313 | 2008 | Clinical Trial | Blood | BiRD regimen as first-line therapy in treatment-naive symptomatic MM: high complete and overall response rates established; served as the pivotal proof-of-concept for the clarithromycin + IMiD strategy |
| 30792190 | 2019 | Phase 2 Clinical Trial | Blood Advances | ClaPd (clarithromycin + pomalidomide + dexamethasone) in 120 RRMM patients with prior lenalidomide exposure; evaluated safety and efficacy in a heavily pretreated population (median 5 prior lines) |
| 24723438 | 2014 | Clinical Study | American Journal of Hematology | Retrospective analysis (24 patients): adding clarithromycin to lenalidomide/dexamethasone at disease progression reversed IMiD resistance; supports a resistance-reversal mechanism |
| 24576165 | 2014 | Phase 2 Clinical Trial | Leukemia & Lymphoma | T-BiRD (thalidomide + clarithromycin + lenalidomide + dexamethasone) in 26 newly diagnosed MM patients; evaluated response and tolerability of this quadruplet oral regimen |
| 34424561 | 2021 | Phase 2 Clinical Trial | American Journal of Hematology | Car-BiRd (carfilzomib → clarithromycin + lenalidomide + dexamethasone consolidation) sequential strategy in newly diagnosed MM; achieved deep responses with reduced corticosteroid toxicity |
| 12685831 | 2002 | Phase 2 Clinical Trial | Leukemia & Lymphoma | BLT-D (clarithromycin + low-dose thalidomide + dexamethasone) in previously treated and untreated MM and Waldenström's macroglobulinemia; established clarithromycin's role as a non-myelosuppressive oral partner |
| 26505646 | 2016 | Preclinical / Translational | Acta Haematologica | Clarithromycin synergistically enhances thalidomide cytotoxicity in myeloma cells in vitro; provides the mechanistic underpinning for IMiD potentiation across combination regimens |
| 12720150 | 2003 | Clinical Study | Seminars in Oncology | Clarithromycin + thalidomide + dexamethasone in Waldenström's macroglobulinemia (a monoclonal IgM disorder closely related to MGUS); demonstrated improved activity over thalidomide monotherapy |
Singapore Market Information
Clarithromycin is currently not registered in Singapore. No active product licences were identified in the regulatory database (0 registrations).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Multiple Phase 2 clinical trials and one completed Phase 3 RCT document Clarithromycin's use within combination regimens for monoclonal gammopathy and multiple myeloma. The mechanistic basis — CYP3A4-mediated IMiD potentiation combined with direct immunomodulatory and anti-tumour effects — is well characterised, and established regimens (BiRD, BLT-D, ClaPd) are already used in clinical practice. However, the Phase 3 RCT result (no significant PFS benefit when added to standard Rd) signals that the benefit may be context-dependent, indicating guardrails are necessary before broader adoption.
To proceed, the following is needed:
- Retrieve detailed MOA data from DrugBank API (CYP3A4 interaction profile, direct anti-tumour pathways) to complete the mechanistic analysis
- Obtain Singapore HSA package insert and label for key warnings, contraindications, and drug interaction data (currently all data gaps)
- Define the specific target subpopulation: MGUS chemoprevention vs. active MM (which line of therapy, which combination backbone)
- Conduct Singapore-specific regulatory pathway assessment for the "repurposed" oncology indication, given current zero-registration status
- Review the Phase 3 RCT (PMID 34021118) results in full to understand which patient subgroups may still derive benefit from clarithromycin addition
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.